Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0BDVZW
ADC Name
USRE47194 ADC-3
Synonyms
USRE47194_ADC-3
   Click to Show/Hide
Organization
Genentech, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Drug-to-Antibody Ratio
3.1
Antibody Name
USRE47194 ADC-3 antibody
Antigen Name
Mucin-16 (MUC16)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
USRE47194 ADC-3 linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 67.8
%
CVCL_0465
Ovarian serous adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
CVCL_0465
Ovarian serous adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
CVCL_0465
Ovarian serous adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 67.80% (Day 40) Moderate MUC16 expression (MUC16++)
Method Description
Mice were treated with a single intravenous dose of the ADCs at 1.5 mg/kg.
In Vivo Model OVCAR-3 CDX model
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 40) Moderate MUC16 expression (MUC16++)
Method Description
Mice were treated with a single intravenous dose of the ADCs at 3 mg/kg.
In Vivo Model OVCAR-3 CDX model
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 40) Moderate MUC16 expression (MUC16++)
Method Description
Mice were treated with a single intravenous dose of the ADCs at 6 mg/kg.
In Vivo Model OVCAR-3 CDX model
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
References
Ref 1 Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.